Safety

Doribax (Doripenem) For Injection

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)

August 2015

Summary View

ADVERSE REACTIONS

Postmarketing Experience
  • renal impairment/failure

 

January 2014

Summary View

5 WARNINGS AND PRECAUTIONS

5.1 Increased Mortality in Ventilator-Associated Bacterial Pneumonia
  • In a clinical trial of patients with ventilator-associated bacterial pneumonia comparing doripenem to imipenem, more subjects receiving doripenem died 23% (31/135) compared to those receiving imipenem 16.7% (22/132) based on 28-day all-cause mortality in the intent-to-treat (ITT) population. Clinical response rates were also lower in the doripenem arm. Doripenem is not approved for the treatment of ventilator-associated bacterial pneumonia.

 

April 2013

Summary View 

ADVERSE REACTIONS

Adverse Reactions from Clinical Trials
  • In a Phase 1 study of healthy subjects receiving doripenem doses greater than the approved dose of 500 mg every 8 hours for 10 to 14 days, the incidence of rash was higher than that observed in subjects who received 500 mg every 8 hours. The rash resolved within 10 days after doripenem administration was discontinued.
 
Postmarketing Experience
  • Thrombocytopenia
  • Stevens-Johnson Syndrome

 

Page Last Updated: 09/10/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English